|
1
|
Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng
T, Yuan Q and Xiao X: The epidemiology and clinical information
about COVID-19. Eur J Clin Microbiol Infect Dis. 39:1011–1019.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zarocostas J: What next for the
coronavirus response? Lancet. 395(401)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Schuivens PME, Buijs M, Boonman-de Winter
L, Veen EJ, de Groot HGW, Buimer TG, Ho GH and van der Laan L:
Impact of the COVID-19 lockdown strategy on vascular surgery
Practice: More major amputation than usual. Ann Vasc Surg.
69:74–79. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tang N, Bai H, Chen X, Gong J, Li D and
Sun Z: Anticoagulant treatment is associated with decreased
mortality in severe coronavirus disease 2019 patients with
coagulopathy. J Thromb Haemost. 18:1094–1099. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mohammad M, Safavi-Naeini P, Solomon SD
and Vardeny O: Potential effects of coronavirus on the
cardiovascular system a review. JAMA Cardiol. 5:831–840.
2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu
Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet.
395:497–506. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gonzalez Cañas E, Gimenez Gaibar A,
Rodriguez Lorenzo L, Castro Rios JG, Martinez Toiran M, Bella Cueto
MR, Bella Burgos B and Espasa Soley M: Acute peripheral arterial
thrombosis in COVID-19. Role of endothelial inflammation. Br J
Surg. 107:e444–e445. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mehta P, McAuley DF, Brown M, Sanchez E,
Tattersal RS and Manson JJ: HLH Across Speciality Collaboration,
UK. COVID-19: Consider cytokine storm syndromes and
immunosuppression. Lancet. 395:1033–1034. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Rogers MAM, Levine DA, Blumberg N,
Flanders SA, Chopra V and Langa KM: Triggers of hospitalization for
venous thromboembolism. Circulation. 125:2092–2099. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Konstantinides SV, Meyer G, Becattini C,
Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings
CS, Jiménez D, et al: 2019 ESC Guidelines for the diagnosis and
management of acute pulmonary embolism developed in collaboration
with the European respiratory society (ERS). Eur Heart J.
41:543–603. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Samama MM, Cohen AT, Darmon JY, Desjardins
L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG
and Weisslinger N: A comparison of enoxaparin with placebo for the
prevention of venous thromboembolism in acutely ill medical
patients. Prophylaxis in Medical Patients with Enoxaparin Study
Group. N Engl J Med. 341:793–800. 1999.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Leizorovicz A, Cohen AT, Turpie AGG,
Olsson CG, Vaitkus PT and Goldhaber SZ: PREVENT Medical
Thromboprophylaxis Study Group. Randomized, placebo-controlled
trial of dalteparin for the prevention of venous thromboembolism in
acutely ill medical patients. Circulation. 10:874–879.
2004.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cohen AT, Davidson BL, Gallus AS, Lassen
MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM and Lensing AWA:
ARTEMIS Investigators. Efficacy and safety of fondaparinux for the
prevention of venous thromboembolism in older acute medical
patients: Randomized placebo controlled trial. BMJ. 332:325–329.
2006.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Schünemann HJ, Cushman M, Burnett AE, Kahn
SR, Beyer-Westendorf J, Spencer FA, Rezende SM, Zakai NA, Bauer KA,
Dentali F, et al: American society of hematology 2018 guidelines
for management of venous thromboembolism: Prophylaxis for
hospitalized and nonhospitalized medical patients. Blood Adv.
2:3198–3225. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kahn SR, Lim W, Dunn AS, Cushman M,
Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, et al:
Prevention of VTE in nonsurgical patients: Antithrombotic therapy
and prevention of thrombosis, 9th ed: American college of chest
physicians evidence-based clinical practice guidelines. Chest. 141
(Suppl 2):e195S–e226S. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bikdeli B, Madhavan MV, Jimenez D, Chuich
T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y,
et al: COVID-19 and thrombotic or thromboembolic disease:
Implications for prevention, antithrombotic therapy, and follow-up:
JACC state-of-the-art review. J Am Coll Cardiol. 75:2950–2973.
2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hunt BJ: Hemostasis at extremes of body
weight. Semin Thromb Hemost. 44:632–639. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
World Health Organization (WHO): Clinical
management of severe acute respiratory infection when novel
coronavirus (2019-nCoV) infection is suspected: Interim guidance,
28 January 2020. WHO, Geneva, 2020.
|
|
19
|
Ho KM and Tan JA: Stratified meta-analysis
of intermittent pneumatic compression of the lower limbs to prevent
venous thromboembolism in hospitalized patients. Circulation.
128:1003–1020. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Spyropoulos AC, Lipardi C, Xu J, Peluso C,
Spiro TE, De Sanctis Y, Barnathan ES and Raskob GE: Modified
IMPROVE VTE risk score and elevated D-dimer identify a high venous
thromboembolism risk in acutely Ill medical population for extended
thromboprophylaxis. TH Open. 4:e59–e65. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Spyropoulos AC, Lipardi C, Xu J, Lu W, Suh
E, Yuan Z, Levitan B, Sugarmann C, De Sanctis Y, Spiro TE, et al:
Improved benefit risk profile of rivaroxaban in a subpopulation of
the MAGELLAN study. Clin Appl Thromb Hemost.
25(1076029619886022)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cohen AT, Spiro TE, Spyropoulos AC,
Desanctis YH, Homering M, Büller HR, Haskell L, Hu D, Hull R,
Mebazaa A, et al: D-dimer as a predictor of venous thromboembolism
in acutely ill, hospitalized patients: A subanalysis of the
randomized controlled MAGELLAN trial. J Thromb Haemost. 12:479–487.
2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Gerotziafas GT, Catalano M, Colgan MP,
Pecsvarady Z, Wautrecht JC, Fazeli B, Olinic DM, Farkas K, Elalamy
I, Falanga A, et al: Guidance for the management of patients with
vascular disease or cardiovascular risk factors and COVID-19:
Position paper from VAS-European independent foundation in
angiology/vascular medicine. Thromb Haemost. 120:1597–1628.
2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sena G and Gallelli G: An increased
severity of peripheral arterial disease in the COVID-19 era. J Vasc
Surg. 72(758)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chiesa R, Kahlberg A, Rinaldi E and Mascia
D: Emergency management of the COVID-19 pandemic in a vascular
surgery department of a large metropolitan hospital in Italy.
Preparation, escalation, de-escalation, and normal activity. J Card
Surg. 36:1632–1636. 2021.PubMed/NCBI View Article : Google Scholar
|
